Dr. Jose Gabriel Improvola, MD

Dr. Improvola practices at TriHealth H in Cincinnati, Ohio.

Dr. Improvola's NPI, 1164749701, was assigned on April 21, 2010. Dr. Improvola holds Indiana license 01073737A.

Dr. Improvola's primary practice is TriHealth H, at 4685 Forest Ave, Cincinnati, OH 45212 in Hamilton County. The practice phone is (513) 569-6577.

Dr. Improvola's primary practice is TriHealth H in Cincinnati, Ohio. Dr. Improvola is also affiliated with Bethesda North Hospital. The medical group on file is TriHealth. Dmand AI also links Dr. Improvola to 5 more hospitals, 3 group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Improvola practices, 9 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Improvola's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dmand AI has Dr. Improvola's licenses on file in 3 states: Indiana, Ohio and Virginia.

CMS data shows 3,095 Medicare services from Dr. Improvola across 25 procedure codes in 2024, for 1,464 Medicare patients. Medicare paid $128,350 for them.

CMS counts 1,464 Medicare patients who saw Dr. Improvola in 2024. The largest group is 65 to 74, with 594 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 1.67, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Improvola's median patient age at 74, with 45% women.

In 2024, Dr. Improvola wrote 2,441 Medicare Part D claims for 500 patients. 82% of them were for generic drugs. CMS names the drug for 2,284 of them, across 38 drugs with 11 or more claims each, at $433,840 in total drug cost. In 2023, CMS named 2,036 claims across 35 drugs.

Dr. Improvola accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 236 general payments to Dr. Improvola from 30 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 57% of the total. Medtronic Vascular, Inc. paid the most, $3,063.